SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
Rhea-AI Summary
SciSparc (Nasdaq: SPRC) and Clearmind (Nasdaq: CMND) announced the publication of a U.S. patent application on Oct 20, 2025 covering a combination therapy of MEAI (5-methoxy-2-aminoindane) and N‑Acylethanolamines such as Palmitoylethanolamide (PEA) to address binge behavior disorders.
The patent application cites multiple binge behaviors including excessive alcohol use, eating disorders, tobacco use, compulsive shopping, and problematic sexual conduct. The filing describes a therapeutic rationale: MEAI to reduce impulsivity and reward-seeking and PEA for anti-inflammatory and neuroprotective support. The collaboration targets conditions including alcohol use disorder, cocaine addiction, obesity, and depression, and cites preclinical data supporting potential efficacy in reducing binge episodes while preserving natural reward pathways.
Positive
- U.S. patent application published on Oct 20, 2025
- Patent covers MEAI + PEA combination for multiple binge behaviors
- Collaboration targets alcohol use disorder, cocaine addiction, obesity, depression
Negative
- Evidence cited is preclinical only; no clinical efficacy or approvals reported
- Patent application publication is not a granted patent and offers provisional protection only
News Market Reaction
On the day this news was published, SPRC gained 12.83%, reflecting a significant positive market reaction. Argus tracked a peak move of +26.3% during that session. Argus tracked a trough of -5.5% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $795K to the company's valuation, bringing the market cap to $7M at that time.
Data tracked by StockTitan Argus on the day of publication.
TEL AVIV, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the publication of a U.S. patent application by the United States Patent and Trademark Office. The patent relates to an innovative combination therapy of MEAI (5-methoxy-2-aminoindane) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing binge behavior disorders.
The patent refers to multiple binge behaviors, including excessive alcohol consumption, eating disorders, tobacco use, compulsive shopping, and problematic sexual conduct. The combination leverages MEAI’s psychedelic properties to reduce impulsivity and reward-seeking, enhanced by PEA’s anti-inflammatory and neuroprotective effects, potentially offering a breakthrough in treating substance use and behavioral addictions without the risks associated with traditional interventions.
SciSparc-Clearmind collaboration, focusing on PEA-MEAI combinations for conditions such as alcohol use disorder, cocaine addiction, obesity, and depression. Preclinical data supports the therapy’s potential efficacy in mitigating binge episodes while preserving natural reward pathways.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.
About Clearmind Medicine Inc. (Nasdaq: CMND) (FSE: CWY)
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Clearmind’s intellectual portfolio currently consists of 19 patent families including 31 granted patents. For further information visit: https://www.clearmindmedicine.com
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward looking statements when discussing the potential benefits and advantages of the new patent application, and that this proprietary combination has the potential to address: excessive alcohol consumption, eating disorders, tobacco use, compulsive shopping, and problematic sexual conduct. Since such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
FAQ
What did SciSparc (SPRC) announce on October 20, 2025?
What disorders does the SPRC-Clearmind patent application target?
Does the SPRC patent application report clinical trial results?
How does the MEAI+PEA combination reportedly work according to the SPRC announcement?
Which conditions will SciSparc and Clearmind focus on with the PEA-MEAI program?
